Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150716 · ClinicalTrials.gov registry record · Phase 1
Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)
A Phase 1 study of Pelizaeus-Merzbacher Disease, sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 7
- Study locations
NCT06150716 is a Phase 1 study of Pelizaeus-Merzbacher Disease that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 24 participants. The trial reports 7 study locations across 4 states.
The verdict
NCT06150716, a Phase 1 study of Pelizaeus-Merzbacher Disease, is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of ION356.
Conditions Studied
Interventions
- DRUG ION356
Study Locations (7)
Other
- Ionis Investigative Site - Le Kremlin-Bicêtre
- Ionis Investigative Site - Göttingen
- Ionis Investigative Site - Tokyo
- Ionis Investigative Site - Amsterdam
Georgia
- Ionis Investigative Site - Atlanta
Pennsylvania
- Ionis Investigative Site - Philadelphia
Utah
- Ionis Investigative Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06150716
The ClinicalTrials.gov registry entry for NCT06150716 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pelizaeus-Merzbacher Disease appearing as the primary indexed condition, and to 1 intervention - of which ION356 is the first listed.
NCT06150716 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Other, Georgia, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06150716 about?
NCT06150716 is a clinical study titled "Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)". The primary purpose of this study is to evaluate the safety and tolerability of ION356.
What is the current status of trial NCT06150716?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-04-10. Estimated completion is 2028-06.
What conditions does trial NCT06150716 study?
This clinical trial studies the following conditions: Pelizaeus-Merzbacher Disease.
What interventions are being tested in trial NCT06150716?
The interventions under investigation include: ION356 (DRUG).
Who is sponsoring clinical trial NCT06150716?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06150716 being conducted?
This trial has 7 study locations across Georgia, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pelizaeus-Merzbacher Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.